EUVIMEDEUVIMED entdecken
Multizentrische Studie

High Prevalence of NASH and Advanced Fibrosis in Type 2 Diabetes: A Prospective Study of 330 Outpatients Undergoing Liver Biopsies for Elevated ALT, Using a Low Threshold

Laurent Castera iD, Cédric Laouenan, Anaïs Vallet-Pichard, Tiphaine Vidal-Trécan, Pauline Manchon, Valérie Paradis, Dominique Roulot, Nathalie Gault, Christian Boitard, Benoit Terris, Hélène Bihan, Jean-Baptiste Julla und 10 weitere

Diabetes Care · 01.07.2023 · 46 (7) · 1354-1362

DOI: 10.2337/dc22-2048 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Diabetes Care, online erschienen am 12.04.2023. Verfasst von Laurent Castera und 21 weiteren Autor:innen. Beteiligte Einrichtung: 1Université Paris Cité, UMR1149 (CRI), INSERM, Paris, France. Hauptthemen laut MEDLINE: Non-alcoholic Fatty Liver Disease, Diabetes Mellitus, Type 2. Die Arbeit wurde bisher 137-mal zitiert (Crossref) und nennt 39 Literaturangaben. Gefördert von: Agence Nationale de la Recherche.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

OBJECTIVE Most people with type 2 diabetes (T2DM) and nonalcoholic steatohepatitis (NASH) or advanced fibrosis (AF) remain undiagnosed, resulting in missed opportunities for early intervention. This multicenter, prospective study assessed the yield of using routinely available data to identify these patients. RESEARCH DESIGN AND METHODS A total of 713 outpatients with T2DM, screened in four diabetology clinics for nonalcoholic fatty liver disease according to American Diabetes Association criteria, were referred to hepatologists for further work-up (Fibrosis-4 and vibration-controlled transient elastography [VCTE]). A liver biopsy was proposed when ALT levels were persistently >20 IU/L in female patients or >30 IU/L in male patients, in the absence of other liver disease. RESULTS Liver biopsies were performed in 360 patients and considered adequate for reading after central review for 330 specimens (median patient age, 59 years; male patients, 63%; median BMI and HbA1c values, 32 and 7.5%, respectively). Prevalence of NASH, AF, and cirrhosis were 58%, 38%, and 10%, respectively. Liver lesions were independently associated with the components of metabolic syndrome but not with the micro- and macrovascular complications of T2DM. Models based on routinely available data with or without VCTE had good accuracy to predict AF (respectively: area under the receiver operating characteristic curve [AUROC], 0.84 and 0.77; and correctly classified 59% and 45%) and NASH (respectively: AUROC, 0.82 and 0.81; 44% and 42%). CONCLUSIONS Despite the use of a low ALT threshold, prevalence of NASH (58%) or AF (38%) was high. Routinely available data had a high yield in identifying patients with T2DM with AF and/or NASH requiring further liver assessment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Non-alcoholic Fatty Liver DiseaseDiabetes Mellitus, Type 2HumansMaleFemaleMiddle AgedProspective StudiesOutpatientsPrevalenceLiverLiver CirrhosisBiopsyFibrosis

Autor:innen und Institutionen

  • 1Université Paris Cité, UMR1149 (CRI), INSERM, Paris, France.
  • 2Service d'hépatologie, Assistance Publique-Hôpitaux de Paris, Hôpital Beaujon, Clichy-la-Garenne, France.
  • 3Université Paris Cité, UMR1137 (IAME), INSERM, Paris, France.
  • 4DEBRC, Assistance Publique-Hôpitaux de Paris, Hôpital Bichat, Paris, France.
  • 5Service d'hépatologie, Assistance Publique-Hôpitaux de Paris, Groupe hospitalier Cochin, Paris, France.
  • 6Centre Universitaire du Diabète et de ses Complications, Assistance Publique-Hôpitaux de Paris, Hôpital Lariboisière, Paris, France.

ORCID-Profile: Laurent Castera

Förderung

  • Agence Nationale de la Recherche

Zitieren

APA

Castera, L., Laouenan, C., Vallet-Pichard, A., Vidal-Trécan, T., Manchon, P., Paradis, V., Roulot, D., Gault, N., Boitard, C., Terris, B., Bihan, H., Julla, J. B., Radu, A., Poynard, T., Brzustowsky, A., Larger, E., Czernichow, S., Pol, S., Bedossa, P., …, & QUID-NASH investigators (2023). High Prevalence of NASH and Advanced Fibrosis in Type 2 Diabetes: A Prospective Study of 330 Outpatients Undergoing Liver Biopsies for Elevated ALT, Using a Low Threshold. Diabetes Care, 46(7), 1354-1362. https://doi.org/10.2337/dc22-2048

Vancouver

Castera L, Laouenan C, Vallet-Pichard A, Vidal-Trécan T, Manchon P, Paradis V, et al. High Prevalence of NASH and Advanced Fibrosis in Type 2 Diabetes: A Prospective Study of 330 Outpatients Undergoing Liver Biopsies for Elevated ALT, Using a Low Threshold. Diabetes Care. 2023;46(7):1354-1362. doi:10.2337/dc22-2048

BibTeX
@article{Castera2023,
  author = {Castera, Laurent and Laouenan, Cédric and Vallet-Pichard, Anaïs and Vidal-Trécan, Tiphaine and Manchon, Pauline and Paradis, Valérie and Roulot, Dominique and Gault, Nathalie and Boitard, Christian and Terris, Benoit and Bihan, Hélène and Julla, Jean-Baptiste and Radu, Alina and Poynard, Thierry and Brzustowsky, Angélique and Larger, Etienne and Czernichow, Sébastien and Pol, Stanislas and Bedossa, Pierre and Valla, Dominique and Gautier, Jean-François and QUID-NASH investigators, QUID-NASH investigators},
  title = {High Prevalence of NASH and Advanced Fibrosis in Type 2 Diabetes: A Prospective Study of 330 Outpatients Undergoing Liver Biopsies for Elevated ALT, Using a Low Threshold},
  journal = {Diabetes Care},
  year = {2023},
  volume = {46},
  number = {7},
  pages = {1354--1362},
  doi = {10.2337/dc22-2048}
}
Kostenlos starten →